Identification of potential druggable targets for endometriosis through Mendelian randomization analysis
Related Experiment Video
Updated: May 11, 2026
Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue
Published on: January 6, 2012
Peng Chen1, Xin Wei1, Xiao-Ke Li1
1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Liaoning, Shenyang, China.
Introduction:
Endometriosis (EM) is a widely recognized disorder in gynecological endocrinology. Although hormonal therapies are frequently employed for EM, their side effects and outcome limitations underscore the need to explore the genetic basis and potential drug targets for developing innovative therapeutic approaches. This study aimed to identify both cerebrospinal fluid (CSF) and plasma protein markers as promising therapeutic targets for EM.
Methods:
We utilized Mendelian randomization (MR) analysis to explore potential disease-causing proteins, utilizing genetic datasets from genome-wide association studies (GWAS) and protein quantitative trait loci (pQTL) analyses. We applied a range of validation techniques, including reverse causality detection, phenotype scanning, Bayesian co-localization (BC) analysis, and external validations to substantiate our findings. Additionally, we conducted a protein-protein interaction (PPI) network as well as functional enrichment analyses to unveil potential associations among target proteins.
Results:
MR analysis revealed that a decrease of one standard deviation (SD) in plasma R-Spondin 3 (RSPO3) level had a protective effect on EM (OR = 1.0029; 95% confidence interval (95% CI): 1.0015-1.0043; P = 3.2567e-05; Bonferroni P < 5.63 × 10-5). BC analysis showed that RSPO3 shared the same genetic variant with EM (coloc.abf-PPH4 = 0.874). External validation further supported this causal association. Galectin-3 (LGALS3; OR = 0.9906; 95% CI: 0.9835-0.9977; P = 0.0101), carboxypeptidase E (CPE; OR = 1.0147; 95% CI: 1.0009-1.0287; P = 0.0366), and alpha-(1,3)-fucosyltransferase 5 (FUT5; OR = 1.0053; 95% CI: 1.0013-1.0093; P = 0.002) were detected as potential targets for EM in CSF. PPI analysis showed that fibronectin (FN1) had the highest combined score. Furthermore, several EM-linked proteins were involved in the glycan degradation pathway.
Discussion:
In conclusion, this comprehensive study offers valuable insights into potential drug targets for EM, with RSPO3 emerging as a promising candidate. Additionally, mechanistic roles of FN1, glycan degradation pathway, LGALS3, CPE, and FUT5 in EM warrant further investigation.
Insights
This study identifies R-Spondin 3 (RSPO3) as a potential therapeutic target for endometriosis (EM). Lower RSPO3 levels show a protective effect, suggesting new avenues for EM treatment beyond hormonal therapies.
Area of Science:
- Gynecological endocrinology
- Genetics
- Proteomics
Background:
- Endometriosis (EM) is a common gynecological disorder.
- Current hormonal therapies for EM have limitations and side effects.
- There is a need for novel therapeutic targets and approaches for EM.
Purpose of the Study:
- To identify cerebrospinal fluid (CSF) and plasma protein markers as potential therapeutic targets for endometriosis.
- To explore the genetic basis of endometriosis and discover novel drug targets.
Main Methods:
- Mendelian randomization (MR) analysis was performed using genome-wide association studies (GWAS) and protein quantitative trait loci (pQTL) data.
- Validation techniques included reverse causality detection, phenotype scanning, Bayesian co-localization (BC) analysis, and external validation.
- Protein-protein interaction (PPI) network and functional enrichment analyses were conducted.
Main Results:
- Decreased plasma R-Spondin 3 (RSPO3) levels demonstrated a protective effect against endometriosis (OR = 1.0029).
- Bayesian co-localization confirmed shared genetic variants between RSPO3 and endometriosis.
- Potential CSF protein targets for EM include Galectin-3 (LGALS3), carboxypeptidase E (CPE), and alpha-(1,3)-fucosyltransferase 5 (FUT5).
Conclusions:
- R-Spondin 3 (RSPO3) is a promising therapeutic target for endometriosis.
- Further investigation into the roles of fibronectin (FN1), LGALS3, CPE, and FUT5 in endometriosis is warranted.
- The glycan degradation pathway may be mechanistically involved in endometriosis.
